



28-29 September 2023,

Kragujevac, Serbia


www.iccbikg2023.kg.ac.rs

2nd International Conference on Chemo and Bioinformatics

ICCBIKG_2023



BOOK OF PROCEEDINGS





2nd International Conference on Chemo and Bioinformatics
ICCBIKG 2023

BOOK OF PROCEEDINGS

September 28-29, 2023
Kragujevac, Serbia

Sponsored by



2nd International Conference on Chemo and BioInformatics, Kragujevac, September 28-29, 2023, Serbia.

Editors:

Professor Dr. Zoran Marković

Professor Dr. Nenad Filipović

Technical Editors:

Jelena Živković

Marko Antonijević

Dr. Žiko Milanović

Dr. Vladimir Simić

Proofreading:

Marijana Dimović

Publisher:

Institute for Information Technologies, University of Kragujevac, Serbia, Jovana Cvijića bb, 2023

Press:

„Grafo Ink“, Kragujevac

Impression:

120 copies

CIP - Каталогизacija u publikaciji - Narodna biblioteka Srbije, Beograd

54:004(048)(0.034.2)

57+61]:004(082)(0.034.2)

INTERNATIONAL Conference on Chemo and BioInformatics (2 ; 2023 ; Kragujevac) Book of Proceedings [Elektronski izvor] / 2nd International Conference on Chemo and BioInformatics, ICCBIKG 2023, September 28-29, 2023 Kragujevac, Serbia ; [editors Zoran Marković, Nenad Filipović]. - Kragujevac : University, Institute for Information Technologies, 2023 (Kragujevac : Grafo Ink). - 1 USB fleš memorija ; 1 x 2 x 6 cm

Sistemski zahtevi: Nisu navedeni. - Nasl. sa naslovne strane dokumenta. - Tiraž 120. - Bibliografija uz svaki rad.

ISBN 978-86-82172-02-4

a) Хемија -- Информациона технологија -- Зборници b) Биомедицина -- Информациона технологија -- Зборници

COBISS.SR-ID 125908489

***In silico* Drug-Likeness, Pharmacokinetic and other ADME properties of 2-(aminomethyl)cyclopropane-1,1-dicarboxylic acid**

Marina D. Kostić^{1*}, Jovana S. Marjanović², Sven Mangelinckx³, Vera M. Divac²

¹ University of Kragujevac, Institute for Information Technologies, Department of Science, Kragujevac, Serbia e-mail: marinak@uni.kg.ac.rs

² University of Kragujevac, Faculty of Science, Department of Chemistry, Kragujevac, Serbia; e-mail: vera.divac@pmf.kg.ac.rs, jovana.marjanovic@pmf.kg.ac.rs

³ Ghent University, Faculty of Bioscience Engineering, Department of Green Chemistry and Technology; e-mail: sven.mangelinckx@ugent.be

* *Corresponding author*

DOI: 10.46793/ICCBi23.455K

Abstract: Herein we present the results of *in silico* determination of Drug-Likeness, Pharmacokinetic and other ADME properties of 2-(aminomethyl)cyclopropane-1,1-dicarboxylic acid as an example constrained γ -amino dicarboxylic acid. The results of *in silico* screening of drug-likeness, pharmacokinetic and other ADME (absorption, distribution, metabolism and elimination) properties of 2-(aminomethyl)cyclopropane-1,1-dicarboxylic acid have revealed that this compound is not able to cross the blood-brain barrier, but it shows good solubility and gastrointestinal absorption. The possible target screening has indicated the family C G protein-coupled receptors as the most probable physiological targets. More specifically, the 2-(aminomethyl)cyclopropane-1,1-dicarboxylic acid has the highest structural similarity with the known compounds that act on metabotropic glutamate receptor, excitatory amino acid transporter and betaine transporter. Taking all the above into consideration, it can be concluded that our investigated compound could be considered as a candidate molecule for further structural transformations that could enable better pharmacological performance and physiochemical properties.

Keywords: amino acids; ADMET; pharmacology

1. Introduction

Taking into consideration that drug discovery can be time-consuming and very expensive process, the application of different predictors for the determination of a potential drug's *in vivo* studies and properties necessary for the administration under physiological conditions, is today a recognizable concept for successful drug design and synthesis. ADME properties (absorption, distribution, metabolism and elimination) are excellent predictors of the potential drug's success. Numerous different *in silico* ADME tools have been developed, all based solely on the use of chemical structures [1-3]. Herein we present the results obtained by

the application of SwissADME tool for the evaluation of pharmacokinetics, drug-likeness and other ADME properties of 2-(aminomethyl)cyclopropane-1,1-dicarboxylic acid as an example of sterically constrained amino acids.

2. Results and Discussions

2-(Aminomethyl)cyclopropane-1,1-dicarboxylic acid **1** (Figure 1) as an example of the unnatural amino acids, previously synthesized by us [4], as an example of sterically constrained gamma amino acids. Taking into consideration that our previous work was directed to the resolution of the synthetic pathway for approaching this compound and that compound has never been screened for pharmacological potential, herein we present the results of it *in silico* determination of Drug-Likeness, Pharmacokinetic and other ADME properties. For this purpose, the SwissADME online tool [3] was used to evaluate pharmacokinetics, drug-likeness and other ADME properties and the obtained data are presented in Table 1. According to the data given in Table 1 it can be noticed that the compound has good water solubility and high gastrointestinal absorption, but no possibility to cross the blood-brain barrier.




Figure 1. 2-(Aminomethyl)cyclopropane-1,1-dicarboxylic acid.

Table 1. Predicted Drug-Likeness, Pharmacokinetic and other ADME properties calculated by SwissADME web tool for 2-(aminomethyl)cyclopropane-1,1-dicarboxylic acid .

| Substrate: 2-(aminomethyl)cyclopropane-1,1-dicarboxylic acid | | | |
|--|---|--------------------------|--------------------------------|
| Physicochemical Properties | | Pharmacokinetics | |
| Formula | C ₁₃ H ₁₄ NO ₄ | GI absorption | High |
| Molecular weight | 159.14 g/mol | BBB permeant | No |
| Fraction Csp ³ | 0.67 | P-gp substrate | No |
| Num. rotatable bonds | 3 | CYP1A2 inhibitor | No |
| Num. H-bond acceptor | 5 | CYP2C19 inhibitor | No |
| Num. H-bond donors | 3 | CYP2C9 inhibitor | No |
| Molar Refractivity | 34.83 | CYP2D6 inhibitor | No |
| TPSA ^{a)} | 100.62 Å ² | CYP3A4 inhibitor | No |
| | | Log Kp (skin permeation) | -9.75 cm/s |
| Lipophilicity | | Drug-Likeness | |
| Log Po/w (iLOGP) | 0.32 | Lipinski | Yes; 0 violation |
| Log Po/w (XLOGP3) | -3.49 | Ghose | No; 3 violations ^{c)} |
| Log Po/w (WLOGP) | -0.88 | Veber | Yes |
| Log Po/w (MLOGP) | -0.98 | Egan | Yes |
| Log Po/w (SILICOS-IT) | -0.088 | Muegge | No; 2 violations ^{d)} |
| Log Po/w ^{b)} | -1.18 | Bioavailability Score | 0.56 |
| Water Solubility | | Medicinal Chemistry | |
| Log S (ESOL) | 1.57 | PAINS | 0 alert |
| Solubility | 5.91e+03 mg/mL; 3.72e+01 mol/L | Brenk | 1 alert: β-keto anhydride |
| Class | Highly soluble | Leadlikeness | No; 1 violation ^{e)} |
| Log S (Ali) | 1.96 | Synthetic accessibility | 1.79 |
| Solubility | 1.44e+04 mg/mL; 9.05e+01 mol/L | | |
| Class | Highly soluble | | |
| Log S (SILICOS-IT) | 0.75 | | |
| Solubility | 3.95e+02 mg/mL; 5.62e+00 mol/L | | |
| Class | Soluble | | |

a) topological polar surface area; b) average of all 5 predictions; c) MW<160, WLOGP<-0.4, MR<40
d) MW<200, XLOGP3<-2 e) molecular weight <250

The possible intracellular targets of 2-(aminomethyl)cyclopropane-1,1-dicarboxylic acid are given in Figure 2. As it can be seen, our compound has appeared to act on family C G protein-

coupled receptors. C G protein-coupled receptors are transmembrane proteins of the mammalian genome that became pharmaceutically interesting due to the fact that they represent targets of the many approved drugs. More specifically, the 2-(aminomethyl)cyclopropane-1,1-dicarboxylic acid has the highest structural similarity with the known compounds that act on metabotropic glutamate receptor, excitatory amino acid transporter and betaine transporter.




Figure 2. Target prediction of 2-(aminomethyl)cyclopropane-1,1-dicarboxylic acid.

3. *In silico* Drug-Likeness, Pharmacokinetic and other ADME properties study

The physicochemical, ADME, and drug-likeness parameters were computed using the SwissADME online program [3]. This software was used to calculate basic physicochemical properties including topological polar surface area (TPSA) and molecular refractivity. Lipophilicity was estimated through iLOGP, XLOGP3, WLOGP, MLOGP, and SILICOS-IT models from which an average value of all five predictions $\log P_{o/w}$ was determined. The solubility ($\log S$) was calculated by three different models: ESOL, Ali, and SILICOS-IT. Drug-likeness evaluation was based on Lipinski, Ghose, Veber, Egan and Muegge rules of 5. The Abbot Bioavailability scores were computed to predict the probability of a compound having at least 10% oral bioavailability by relying on total charge, TPSA, and violation of the Lipinski's filter. From pharmacokinetic properties gastrointestinal (GI) absorption, blood-brain barrier (BBB) permeation, inhibition of the cytochrome P450 system, permeability glycoprotein (P-gp) substrate and the skin permeation coefficient (k_p) were calculated. Also, tested compounds are screened through PAINS and Brenk filters and Lead likeness potential and synthetic accessibility are calculated.

4. Conclusions

The results of *in silico* screening of drug-likeness, pharmacokinetic and other ADME properties of 2-(aminomethyl)cyclopropane-1,1-dicarboxylic acid have revealed that this compound is not able to cross the blood-brain barrier, but it shows good solubility and gastrointestinal absorption. The possible target screening has indicated the family C G

protein-coupled receptors as the most probable physiological targets. Taking all the above into consideration, it can be concluded that our investigated compound could be considered as a candidate molecule for further structural transformations that could enable better pharmacological performance and physiochemical properties.

Acknowledgment

This research is funded by the Ministry of Education and Ministry of Science, Technological Development and Innovation, Republic of Serbia, Grants: (Agreement No. 451-03-47/2023-01/ 200122 and 451-03-47/2023-01/200378).

References

- [1] A. Effinger, C.M. O'Driscoll, M. McAllister, N. Fotaki., *In Vitro and In Silico ADME Prediction*, in: A. Talevi, P. Quiroga (Eds.), *ADME Processes in Pharmaceutical Sciences*, Springer, 2018.
- [2] S. Kar, J. Leszczynski., *Open access in silico tools to predict the ADMET profiling of drug candidates*, *Expert Opin Drug Discov* 15 (2015) 1473–1487.
- [3] A. Daina, O. Michielin, V. Zoete., *SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules*, *Sci Rep* 7 (2017) 42717.
- [4] S. Mangelinckx, M. Kostic, S. Backx, B. Petrovic, N. De Kimpe., *Synthesis of racemic 2-(aminomethyl)cyclopropane-1,1-dicarboxylic acid as a new constrained γ -amino dicarboxylic acid bypassing alkyl 3-aza-2-oxobicyclo[3.1.0]hexane-1-carboxylates*, *Eur J Org Chem*, 31 (2019) 5187-5189.